Immune-Enhanced iMSCs Revolutionize Therapeutics & Research
Method and Usage of Immune Potent iMSCs From Human Derived Mesenchymal Stem Cells
Tags: The University of Hong Kong, Hong Kong, Healthcare & Lifesciences
This HKU innovation addresses the limitations of mesenchymal stem cells (MSCs), such as senescence and low proliferation, by reprogramming human-derived MSCs into induced pluripotent stem cells (iPSCs) and subsequently into immune-potent iMSCs. These iMSCs mimic primary MSCs closely in gene expression and surface markers while outperforming them in immunomodulatory functions. The technology has shown promising applications in autoimmune and inflammatory diseases, enhancing immune response in in vitro and in vivo tests. Patents are filed in China, the US, and Hong Kong, positioning this method for pharmaceutical development and research tools. This development is poised to address a growing market projected to reach $6.1 billion by 2028.
IP Type or Form Factor: Patent Pending; Process & Method; Material
TRL: 4 - minimum viable product built in lab
Industry or Tech Area: Biotechnology; Pharmaceutical Engineering
